Literature DB >> 1283321

Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination.

M J Coppes1, L Bonetta, A Huang, P Hoban, S Chilton-MacNeill, C E Campbell, R Weksberg, H Yeger, A E Reeve, B R Williams.   

Abstract

Loss of heterozygosity (LOH) for polymorphic markers is a frequently occurring event in some tumors, reflecting the role of allele loss in the development of these tumors. We have determined LOH in 38 cases of Wilms tumor for the 2 known loci on chromosome arm 11p and for a newly detected locus on chromosome arm 16q. Only 7 of the 38 tumors studied showed reduction to homozygosity of 11p13 markers. In 4 of these tumors, reduced expression of WT1 and WIT1, genes located at 11p13 and implicated in Wilms tumorigenesis, was noted. However, this was also found in 2 of 7 tumors showing LOH exclusively of 11p15 markers and in 15 of the remaining 24 tumors in which there was no LOH for 11p markers. This suggests that events not involving mitotic recombination or chromosome nondisjunction are the most common mechanisms for mutations at the 11p Wilms tumor locus. We also noted that mitotic recombination involving 11p15 loci occurred in addition to reduced expression of the 11p13 locus genes in 2 tumors, suggesting a possible interaction between these 2 loci. In addition, LOH for 16q markers was observed in 6 tumors. In one case this was coincident with reduction of WT1 and WIT1 gene expression, and in 3 other cases it occurred in addition to 11p LOH. This indicates that an additional locus on 16q is likely to be involved in Wilms tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283321     DOI: 10.1002/gcc.2870050408

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

Review 1.  Pediatric oncology.

Authors:  Andrew M Davidoff
Journal:  Semin Pediatr Surg       Date:  2010-08       Impact factor: 2.754

2.  Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.

Authors:  A K Charles; K W Brown; P J Berry
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

3.  The long and short of chromosome 11 in breast cancer.

Authors:  I F Newsham
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

4.  A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1.

Authors:  R W Johnstone; R H See; S F Sells; J Wang; S Muthukkumar; C Englert; D A Haber; J D Licht; S P Sugrue; T Roberts; V M Rangnekar; Y Shi
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

5.  Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study.

Authors:  A K Charles; S Mall; J Watson; P J Berry
Journal:  Mol Pathol       Date:  1997-06

6.  Homozygous somatic Wt1 point mutations in sporadic unilateral Wilms tumor.

Authors:  M J Coppes; G J Liefers; P Paul; H Yeger; B R Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

7.  A common region of loss of heterozygosity in Wilms' tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5.

Authors:  C Besnard-Guérin; I Newsham; R Winqvist; W K Cavenee
Journal:  Hum Genet       Date:  1996-02       Impact factor: 4.132

8.  Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor.

Authors:  T Taniguchi; M J Sullivan; O Ogawa; A E Reeve
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

Review 9.  Wilms tumour: diagnosis and treatment.

Authors:  M J Coppes; J E Wolff; M L Ritchey
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.930

Review 10.  Towards an understanding of Wilms' tumour.

Authors:  K A Williamson; V Van Heyningen
Journal:  Int J Exp Pathol       Date:  1994-06       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.